BACKGROUND: In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials. METHOD: A descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis. RESULTS: The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials' purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable. CONCLUSIONS: Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social-emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.
BACKGROUND: In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials. METHOD: A descriptive and explorative qualitative design was used. Fourteen cancerpatients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis. RESULTS: The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials' purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable. CONCLUSIONS:Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social-emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.
Authors: Daniel P Sulmasy; Alan B Astrow; M Kai He; Damon M Seils; Neal J Meropol; Ellyn Micco; Kevin P Weinfurt Journal: Cancer Date: 2010-08-01 Impact factor: 6.860
Authors: A Italiano; C Massard; R Bahleda; A-L Vataire; E Deutsch; N Magné; J-P Pignon; G Vassal; J-P Armand; J-C Soria Journal: Ann Oncol Date: 2007-11-27 Impact factor: 32.976
Authors: Sam Horng; Ezekiel J Emanuel; Benjamin Wilfond; Jonathan Rackoff; Karen Martz; Christine Grady Journal: N Engl J Med Date: 2002-12-26 Impact factor: 91.245
Authors: C Han; J P Braybrooke; G Deplanque; M Taylor; D Mackintosh; K Kaur; K Samouri; T S Ganesan; A L Harris; D C Talbot Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: Karine Dubé; Lara Hosey; Kate Starr; Liz Barr; David Evans; Erin Hoffman; Danielle M Campbell; Jane Simoni; Jeremy Sugarman; John Sauceda; Brandon Brown; Karen L Diepstra; Catherine Godfrey; Daniel R Kuritzkes; David A Wohl; Rajesh Gandhi; Eileen Scully Journal: AIDS Res Hum Retroviruses Date: 2020-04 Impact factor: 2.205
Authors: Sarah B Garrett; Christopher J Koenig; Laura Trupin; Fay J Hlubocky; Christopher K Daugherty; Anne Reinert; Pamela Munster; Daniel Dohan Journal: Support Care Cancer Date: 2017-05-09 Impact factor: 3.603
Authors: Sarah B Garrett; Thea M Matthews; Corey M Abramson; Christopher J Koenig; Fay J Hlubocky; Christopher K Daugherty; Pamela N Munster; Daniel Dohan Journal: JCO Oncol Pract Date: 2019-10-11
Authors: Betty R Ferrell; Carly L Paterson; Mark T Hughes; Vincent Chung; Marianna Koczywas; Thomas J Smith Journal: J Palliat Med Date: 2017-06-13 Impact factor: 2.947
Authors: K M Islam; Samuel T Opoku; Bettye A Apenteng; Ann Fetrick; June Ryan; M Copur; Addison Tolentino; Irfan Vaziri; Apar K Ganti Journal: J Cancer Educ Date: 2014-12 Impact factor: 2.037